Loading...
•
Mar 31, 2021
Liquidia Q1 2021 Earnings Report
Liquidia reported financial results for the first quarter of 2021, highlighted by doubling the market opportunity for Treprostinil Injection and the resubmission of the New Drug Application for LIQ861.
Key Takeaways
Liquidia reported a revenue of $3.1 million for Q1 2021, a significant increase compared to no revenue in Q1 2020. The company's net loss decreased to $9.2 million from $14.8 million in the same period last year. They also reduced annual net spending by more than 40% and strengthened their financial position through a private placement and a new credit facility.
Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery.
Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder.
Improved financial position with private placement and access to new credit facility.
Net loss decreased to $9.2 million, or $0.21 per share, compared to a net loss of $14.8 million, or $0.52 per share, for the quarter ended March 31, 2020.
Liquidia
Liquidia
Liquidia Revenue by Segment
Revenue by Segment
Promotion Agreement Revenue
CapyFin.com Forward Guidance
Liquidia expects potential value-creating events in 2021 and 2022 as it progresses with its strategic initiatives and FDA review of LIQ861.
Positive Outlook
- Enabled subcutaneous delivery of generic Treprostinil Injection, providing lower cost option to all patients on branded Remodulin.
- Resubmitted NDA for LIQ861 (treprostinil) Inhalation Powder for the treatment of Pulmonary Arterial Hypertension (PAH).
- Management implemented measures that reduced net annual spending in 2021 by more than 40% compared to 2020.
- The Company also refinanced its former credit facility with a new facility through Silicon Valley Bank that provides interest-only payments for 24 months.
- The Company raised $21.7 million in April 2021 by entering a common stock purchase agreement with certain institutional investors led by Caligan Partners LP.
Challenges Ahead
- Actively involved in Hatch-Waxman litigation brought by United Therapeutics Corporation.
- Pursuing inter partes review (“IPR”) of certain related patents at the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
- A decision by the PTAB whether to institute an IPR related to the ‘793 patent is expected in the third quarter of 2021.
- Unless the Hatch-Waxman litigation is resolved earlier, the statutory 30-month regulatory stay as a result of the Hatch-Waxman litigation will expire in October 2022.
- Forward-looking statements involve significant risks and uncertainties and actual results could differ materially.